viroporin
small
virusencod
protein
abl
permeabil
membran
ion
small
molecul
famili
protein
includ
vpu
eprotein
channel
coronavirus
ion
channel
hepat
c
viru
hcv
viroporin
commonli
small
transmembran
tm
protein
contain
sever
ident
selfoligomer
subunit
form
function
ion
channel
howev
sequenc
similar
among
viroporin
famili
low
function
channel
differ
subunit
size
stoichiometri
topolog
viroporin
crucial
viral
pathogen
owe
involv
sever
step
viral
life
cycl
main
activ
cell
entri
virion
assembl
releas
infect
cell
protein
influenza
viru
equilibr
ph
across
viral
membran
cell
entri
facilit
rna
releas
across
transgolgi
membran
infect
cell
viral
matur
protein
hcv
believ
act
intracellular
ph
shunt
contribut
deacidif
endosom
virionload
particl
assist
assembl
releas
virion
well
promot
inflammatori
signal
owe
role
viral
life
cycl
structur
differ
human
channel
viral
protein
consid
ideal
antivir
drug
target
sever
compound
block
viroporin
ionchannel
activ
identifi
two
adamantan
base
compound
amantadin
rimantadin
first
us
food
drug
administrationapprov
drug
treatment
influenza
infect
compound
inhibit
protein
block
proton
conduct
also
found
adamantanebas
compound
block
hcv
ionchannel
activ
abolish
inflammatori
signal
liver
macrophag
structur
determin
viroporin
physiolog
condit
difficult
due
hydrophob
dynam
natur
protein
avail
viroporin
structur
reveal
unexpect
architectur
help
understand
oper
channel
addit
bind
mode
sever
ionchannel
blocker
reveal
provid
guidanc
design
inhibitor
sever
structur
protein
complex
adamantan
solv
structur
show
tetram
suggest
two
possibl
bind
model
adamantan
porebind
model
exterior
interfacebind
model
porebind
model
one
adamantan
molecul
physic
block
ion
channel
break
continu
water
wire
channel
critic
proton
conduct
exterior
interfacebind
model
four
adamantan
molecul
bind
alloster
extern
lipidfac
pocket
adjac
monom
thu
induc
conform
chang
tm
helic
favor
close
state
channel
later
confirm
porebind
model
pharmacolog
relev
model
account
antivir
activ
amantadin
rimantadin
unfortun
natur
occur
drugresist
mutat
gradual
decreas
adamantan
inhibit
abil
predomin
amantadineresist
form
repres
huge
challeng
drug
discoveri
structur
protein
studi
use
nuclear
magnet
reson
nmr
method
molecular
model
show
differ
potenti
topolog
conform
protein
two
tm
domain
tmd
separ
short
hydrophil
cytosol
loop
protom
abl
oligomer
hexamer
heptamer
complex
form
ion
channel
structur
studi
reveal
two
propos
structur
oligomer
form
first
structur
propos
funnellik
architectur
individu
monom
interact
monom
form
hexamer
assembl
second
structur
suggest
flowershap
protein
architectur
unit
interact
neighbor
monom
howev
structur
six
adamantan
molecul
propos
bind
six
equival
hydrophob
pocket
form
residu
two
adjac
monom
previou
studi
shown
dimer
camphor
deriv
cagelik
structur
similar
adamantan
possess
high
antivir
activ
influenza
postul
two
camphor
moieti
bind
two
adjac
site
neighbor
chain
howev
compound
test
protein
exact
mechan
inhibit
compound
unknown
note
cageshap
molecul
might
inhibit
influenza
virus
mechan
elucid
drugbind
mechan
rule
possibl
exterior
interfacebind
model
herebi
report
design
character
dimer
amantadin
rimantadin
exterior
interfacebind
model
correct
dimer
amantadin
rimantadin
compar
better
channelblockag
activ
monomer
amantadin
rimantadin
porebind
model
correct
dimer
amantadin
rimantadin
abl
fit
channel
channel
inhibit
contrast
structur
protein
suggest
presenc
sever
ident
adamantanebind
pocket
six
adamantan
molecul
requir
inhibit
one
protein
molecul
accordingli
combin
two
adamantan
moieti
one
molecul
might
lead
supraaddit
increas
potenc
compar
correspond
monoval
ligand
test
hypothesi
synthes
symmetr
dimer
adamantan
analog
variou
alkylspac
length
find
optimum
distanc
allow
simultan
bind
two
adamantan
ring
describ
design
synthesi
symmetr
dimer
adamantan
deriv
variou
alkylspac
length
determin
inhibitori
activ
two
viroporin
channel
influenza
viru
protein
hcv
appli
start
materi
commerci
avail
alfa
aesar
sigmaaldrich
use
receiv
stir
solut
respect
dicarboxyl
acid
mmol
dri
chloroform
ml
oxalyl
chlorid
ml
mmol
ad
dropwis
follow
addit
two
drop
dri
dimethylformamid
reaction
mixtur
left
stir
room
temperatur
rt
hour
toluen
ml
ad
reaction
mixtur
evapor
reduc
pressur
result
acid
chlorid
dissolv
dri
chcl
ml
solut
ad
dropwis
stir
solut
amantadin
g
mmol
dri
triethylamin
ml
mmol
chcl
ml
reaction
mixtur
left
stir
hour
rt
inert
condit
wash
dilut
hcl
ml
combin
organ
layer
wash
water
dri
sodium
sulfat
concentr
reduc
pressur
result
crude
product
pure
enough
use
directli
next
step
without
purif
indic
h
nmr
spectra
compound
mg
obtain
white
solid
mp
mandour
et
al
ml
mmol
dissolv
suffici
amount
dri
tetrahydrofuran
thf
ml
stir
minut
solut
rimantadin
hydrochlorid
g
mmol
dri
thf
ml
ad
dropwis
reaction
mixtur
stir
overnight
rt
inert
condit
satur
solut
nahco
ml
ad
product
extract
ethyl
acet
ml
combin
organ
layer
wash
water
concentr
reduc
pressur
remov
solvent
residu
dissolv
chcl
ml
solut
extract
concentr
hcl
solut
ml
chloroform
phase
wash
water
dri
sodium
sulfat
solvent
evapor
reduc
pressur
residu
purifi
column
chromatographi
dichloromethan
meoh
compound
mg
obtain
white
solid
mp
compound
mg
obtain
yellow
oil
boran
thf
solut
ml
ad
dropwis
stir
mixtur
indic
amount
correspond
amid
dri
thf
ml
heat
reflux
hour
inert
condit
hcl
ml
care
ad
ice
cool
reaction
mixtur
heat
reflux
minut
mixtur
left
cool
rt
basifi
aqueou
ammonia
ice
cool
product
extract
dichloromethan
ml
combin
organ
layer
wash
water
dri
sodium
sulfat
solvent
evapor
reduc
explor
influenza
hcv
adamantan
pressur
residu
purifi
column
chromatographi
chloroform
meoh
ammonia
compound
mg
obtain
white
solid
mg
mp
butylamin
compound
mg
obtain
colorless
oil
mg
precursor
amid
gener
genotyp
gt
specif
cdna
construct
protein
gt
hcv
describ
cell
cultur
transfect
cell
cultur
cm
tissuecultur
petri
dish
mem
sigmaaldrich
st
loui
mo
usa
supplement
fb
thermo
fisher
scientif
waltham
usa
penicillinstreptomycin
sigmaaldrich
co
watersatur
atmospher
experi
cell
plate
polyllysinetr
glass
coverslip
cm
dish
transfect
day
passag
use
cdna
gfp
cdna
gencarri
epoch
life
scienc
sugar
land
tx
usa
measur
perform
day
transfect
electrophysiolog
record
data
analysi
inhibitor
test
twoelectrod
voltageclamp
assay
use
xenopu
laevi
frog
oocyt
microinject
rna
express
either
wild
type
wt
mutant
protein
previous
report
potenc
inhibitor
express
percentag
inhibit
current
observ
minut
incub
compound
measur
inhibit
averag
sd
three
replic
cell
obtain
health
protect
agenc
european
cell
cultur
collect
salisburi
uk
polyllysin
coat
coverslip
transfect
cdna
construct
day
prior
electrophysiolog
record
current
respons
measur
room
temperatur
hold
potenti
mv
use
amplifi
puls
softwar
heka
electron
lambrecht
germani
record
pipett
made
borosil
glass
world
precis
instrument
berlin
germani
use
horizont
puller
sutter
novato
ca
usa
octaflow
system
npi
electron
tamm
explor
influenza
hcv
adamantan
buffer
adjust
use
naoh
hcl
intern
buffer
mm
nmethyldglucamin
mm
ethylen
glycol
tetraacet
acid
mm
hepe
ph
naoh
measur
wholecel
current
cell
perfus
continu
record
buffer
record
interv
inhibitor
dilut
stock
solut
mm
ph
buffer
inhibit
measur
start
baselin
record
extracellular
buffer
ph
second
follow
ph
induc
channel
open
inhibitor
ph
appli
follow
final
control
applic
sometim
control
solut
ph
without
inhibitor
perfus
inhibitor
applic
typic
current
amplitud
pa
doserespons
curv
construct
four
five
cell
per
gt
inhibitor
ic
valu
determin
use
nonlinear
fit
equat
ob
max
ic
ob
observ
current
given
concentr
inhibitor
max
maximum
current
amplitud
observ
absenc
inhibitor
concentr
inhibitor
ic
inhibit
channel
determin
concentrationdepend
inhibit
tm
current
valu
inhibit
gt
amantadin
rimantadin
previous
report
studi
addit
measur
perform
confirm
protein
prepar
use
structur
prepar
wizard
moe
version
save
file
structur
compound
built
minim
use
forc
field
moe
use
gradient
kcal
mol
dock
perform
use
gold
version
bindingsit
residu
defin
specifi
alpha
carbon
use
default
cutoff
radiu
detect
caviti
option
enabl
gold
dock
experi
perform
use
chemplp
score
function
search
effici
genet
algorithm
set
receptor
kept
rigid
compound
complex
gener
cluster
base
rmsd
threshold
set
use
complet
linkag
method
bestrank
pose
popul
cluster
select
final
pose
figur
prepar
use
pymol
version
new
york
ny
usa
target
dimer
amantadin
rimantadin
prepar
twostep
approach
involv
diamid
format
dicarboxyl
acid
ho
c
ch
n
co
h
subsequ
reduct
use
boran
amantadin
seri
dicarboxyl
acid
convert
correspond
acid
chlorid
use
oxalyl
chlorid
crude
acid
chlorid
mmol
react
excess
amantadin
mmol
give
diamid
target
compound
obtain
yield
reduct
boranethf
complex
figur
sinc
rimantadin
commerci
avail
hydrochlorid
altern
conveni
onepot
procedur
amid
format
employ
use
mandour
et
al
diisopropylethylamin
releas
rimantadin
base
salt
use
edci
hclhydroxybenzotriazol
activ
dicarboxyl
acid
rimantadin
amid
obtain
yield
reduc
use
boranethf
complex
give
target
amin
yield
figur
monomer
refer
compound
similar
procedur
employ
butyr
acid
coupl
rimantadin
follow
amid
reduct
use
boranethf
complex
inhibitori
activ
dimer
compound
test
influenza
viru
ion
channel
express
xenopu
oocyt
use
twoelectrod
voltageclamp
techniqu
concentr
amantadin
show
inhibit
wt
protein
use
benchmark
inhibitori
activ
newli
synthes
dimer
compound
show
significantli
lower
inhibitori
activ
rel
monomer
amantadin
figur
compound
activ
show
depend
alkylspac
length
dimer
compound
exhibit
rel
similar
inhibit
inhibitori
activ
refer
monomer
ligand
whose
structur
repres
half
molecul
rimantadin
dimer
approxim
fourfold
indic
introduct
extra
bulki
adamantan
group
detriment
block
ionchannel
activ
examin
experiment
determin
structur
protein
show
ion
channel
limit
pore
size
explor
influenza
hcv
adamantan
ntermin
end
constrict
hydrophob
valv
highresolut
xray
crystal
structur
protein
protein
data
bank
pdb
show
three
intercal
water
cluster
import
stabil
ionchannel
activ
protein
also
drug
bind
upper
layer
water
molecul
stabil
hydrogen
bond
carbonyl
group
lower
layer
water
molecul
lie
deeper
pore
lumen
form
hydrogen
bond
overlay
drugfre
solidst
nmr
structur
protein
pdb
amantadinebound
xray
structur
pdb
show
amantadin
present
pore
lumen
adamantan
cage
place
hydrophob
groov
form
mainli
residu
figur
amantadin
bind
channel
break
continu
water
wire
channel
critic
proton
conduct
posit
charg
ammonium
group
appear
mimic
conduct
hydronium
ion
form
hydrogen
bond
backbon
carbonyl
mediat
upper
layer
water
molecul
importantli
amantadin
bind
channel
posit
charg
ammonium
face
ctermini
channel
suggest
bulki
substitut
amin
group
toler
dimer
compound
secondari
hydrophob
adamantan
cage
introduc
structur
expect
fit
channel
inde
shown
figur
none
dimer
compound
improv
channel
blockag
compar
amantadin
result
also
agreement
previou
structureact
relationship
studi
introduct
bulki
substitu
adamantan
cage
drastic
decreas
compound
inhibitori
activ
small
diamet
protein
pore
limit
size
ligand
fit
pore
result
second
hydrophob
adamantan
moieti
introduc
dimer
compound
accommod
insid
pore
lumen
explain
low
inhibitori
activ
dimer
compound
rel
monomer
amantadin
ligand
inhibitori
activ
dimer
compound
evalu
mutant
form
figur
repres
predomin
amantadineresist
form
dimer
compound
show
lower
inhibitori
activ
compar
amantadin
could
explain
dimer
compound
lack
adamantanenh
ch
aryl
pharmacophor
inhibitor
nevertheless
activ
appear
depend
alkylspac
length
within
dimer
amantadin
seri
increas
inhibitori
activ
observ
increas
spacer
length
dimer
link
tencarbon
spacer
exhibit
highest
inhibitori
activ
previou
solut
nmr
structur
inhibitorbound
structur
show
inhibitor
bind
mutant
flip
orient
rel
mandour
et
al
channel
specif
amino
group
mutantbound
inhibitor
orient
upward
toward
ntermin
end
till
compound
report
possess
inhibitori
activ
mutant
form
share
gener
adamantanenh
ch
aryl
pharmacophor
figur
posit
charg
ammonium
group
heteroaryl
moieti
inhibitor
form
watermedi
interact
amid
residu
dimer
compound
polar
aryl
group
miss
explain
lack
efficaci
inhibit
channel
summari
lack
channel
blockag
dimer
amantadin
rimantadin
analog
mutant
consist
previous
propos
drugbind
mechan
confirm
porebind
model
pharmacolog
relev
drugbind
model
inhibitori
activ
compound
test
channel
gt
express
cell
tabl
amantadin
rimantadin
known
inhibitor
activ
block
lysosom
deacidif
lower
current
patchclamp
measur
thu
use
benchmark
comparison
dimer
adamantan
show
similar
potenc
respect
monomer
analog
gt
test
inhibitori
activ
dimer
amantadin
seri
show
compound
least
potent
amantadin
eightfold
potent
rimantadin
dimer
compound
least
potent
amantadin
equipot
rimantadin
posit
charg
amino
group
appear
import
bind
compound
secondari
amin
ic
nm
wherea
correspond
amid
analog
show
inhibitori
activ
ic
nm
hand
posit
charg
amin
group
appear
less
import
inhibit
gt
compound
show
compar
potenc
gt
result
show
depend
activ
dimer
compound
alkylspac
length
dimer
compound
show
rel
similar
potenc
test
gt
suggest
compound
similar
bind
mode
despit
increas
amount
structur
data
consensu
conform
exist
natur
infect
structur
impact
propos
bind
mode
compound
may
differ
depend
model
accordingli
consid
two
avail
nmr
structur
protein
develop
hypothes
upon
bind
mode
second
adamantan
moieti
two
homolog
model
one
gt
studi
strain
previous
construct
use
nmr
structur
hcv
pdb
templat
model
nmrmd
structur
monomer
form
templat
model
although
exact
bind
mode
amantadinerimantadin
clearli
understood
yet
gener
agre
bind
membranefac
pocket
center
residu
number
structur
examin
model
show
distanc
atom
two
explor
influenza
hcv
adamantan
adjac
adamantanebind
site
respect
second
adamantan
moieti
compound
shortest
spacer
span
distanc
thu
bind
neighbor
adamantanebind
site
locat
adjac
monom
also
support
preliminari
dock
studi
first
adamantan
ring
dimer
compound
show
similar
bind
mode
amantadin
second
adamantan
appear
protrud
anoth
caviti
figur
b
may
suggest
presenc
secondari
adamantanebind
site
futur
sitedirect
mutagenesi
would
need
confirm
unambigu
bind
mode
suggest
dock
studi
inhibitori
activ
adamantan
vari
differ
gt
studi
gtdepend
sensit
multipl
inhibitor
previous
report
amantadin
could
inhibit
ionchannel
activ
gt
similarli
also
observ
hand
extra
ethyl
group
insert
adamantan
ring
amino
group
present
rimantadin
led
least
increas
potenc
compar
amantadin
indic
better
fit
adamantan
pocket
could
suggest
size
adamantan
pocket
gt
might
bigger
gt
amantadin
could
induc
conform
chang
necessari
favor
close
state
protein
previou
nmr
md
simul
experi
protein
report
presenc
prolin
residu
posit
form
kink
carboxytermin
end
tilt
toward
adjac
monom
form
propos
adamantan
primari
bind
pocket
examin
protein
sequenc
show
gt
lack
prolin
figur
prolin
residu
tm
helix
typic
chang
orient
helix
caus
kink
even
break
helix
common
behavior
result
inabl
act
hydrogenbond
donor
tertiari
amid
steric
interfer
cyclic
side
chain
residu
preced
helic
turn
lack
prolin
gt
could
affect
kink
angl
caus
possibl
chang
size
adamantanebind
pocket
could
explain
low
inhibitori
activ
amantadin
dimer
compound
bulki
could
overcom
amantadin
resist
gt
show
even
higher
potenc
rimantadin
higher
activ
observ
dimer
amantadin
rel
monomer
amantadin
could
attribut
either
better
fit
larg
adamantan
pocket
simultan
bind
two
adamantan
ring
primari
secondari
pocket
induc
conform
chang
necessari
favor
close
state
protein
futur
pointmut
studi
introduc
prolin
posit
protein
resist
gt
help
better
understand
bind
mode
dimer
compound
present
studi
synthes
seri
dimer
adamantan
compound
either
amantadin
rimantadin
pharmacophor
link
alkyl
spacer
variou
length
antivir
activ
compound
studi
two
viroporin
upon
test
protein
extra
adamantan
moieti
caus
decreas
potenc
rel
refer
monomer
compound
amantadin
rimantadin
impli
dimer
could
accommod
either
proton
channel
find
although
disappoint
consist
previous
propos
ligandbind
mechan
ligand
bind
posit
charg
ammonium
face
ctermin
inhibitor
need
adamantanenh
ch
aryl
pharmacophor
bind
channel
aryl
group
face
ntermin
hand
dimer
could
lodg
structur
protein
abl
address
differ
adamantan
sensit
among
variou
gt
hcv
dimer
analog
equipot
monomer
refer
ligand
test
hcv
gt
potent
amantadin
gt
respect
posit
charg
amino
group
appear
import
bind
amantadin
channel
gt
less
import
bind
gt
result
help
better
understand
bind
mode
adamantan
protein
summari
symmetr
dimer
adamantan
compound
appear
promis
inhibitor
across
gt
hcv
may
constitut
class
promis
directact
antivir
drug
